• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Rapport Therapeutics Inc.

    2/13/25 4:15:06 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Rapport Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    75383L102

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    Third Rock Ventures V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,135,233.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,135,233.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,135,233.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    Third Rock Ventures GP V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,135,233.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,135,233.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,135,233.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    TRV GP V, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,135,233.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,135,233.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,135,233.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    19.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    Third Rock Ventures VI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    969,218.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    969,218.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    969,218.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    Third Rock Ventures GP VI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    969,218.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    969,218.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    969,218.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    75383L102


    1Names of Reporting Persons

    TRV GP VI, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    969,218.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    969,218.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    969,218.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Rapport Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1325 Boylston Street, Suite 401, Boston, MA 02215
    Item 2. 
    (a)Name of person filing:

    (i) Third Rock Ventures V, L.P. ("TRV V"); (ii) Third Rock Ventures GP V, L.P. ("TRV GP V"), which is the sole general partner of TRV V; (iii) TRV GP V, LLC ("TRV GP V LLC"), which is the sole general partner of TRV GP V; (iv) Third Rock Ventures VI, L.P. ("TRV VI"); (v) Third Rock Ventures GP VI, L.P. ("TRV GP VI"), which is the sole general partner of TRV VI; and (vi) TRV GP VI, LLC ("TRV GP VI LLC"), which is the sole general partner of TRV GP VI.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 201 Brookline Ave, Suite 1401, Boston, MA 02215.
    (c)Citizenship:

    Each of TRV V, TRV GP V, TRV VI and TRV GP VI is a Delaware limited partnership. Each of TRV GP V LLC and TRV GP VI LLC is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    75383L102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) TRV V directly owns 7,135,233 shares of Common Stock (the "V Shares") (ii) TRV GP V is the general partner of TRV V and may be deemed to beneficially own the V Shares. (iii) TRV GP V LLC is the general partner of TRV GP V and may be deemed to beneficially own the V Shares. (iv) TRV VI directly owns 969,218 shares of Common Stock (the "VI Shares"). (v) TRV GP VI is the general partner of TRV VI and may be deemed to beneficially own the VI Shares. (vi) TRV GP VI LLC is the general partner of TRV GP VI and may be deemed to beneficially own the VI Shares. Each of TRV V, TRV GP V, and TRV GP V LLC, on the one hand, and TRV VI, TRV GP VI and TRV GP VI LLC, on the other hand, disclaim the existence of a "group" for purposes of Rule 13d-5 of the Securities Exchange Act of 1934, as amended, and nothing contained in this report shall be deemed an admission that any such group exists or may exist.
    (b)Percent of class:

    The V shares represent approximately 19.5% of the outstanding shares of Common Stock. The VI shares represent approximately 2.7% of the outstanding shares of Common Stock. The percent of class was calculated based on 36,576,457 shares of common stock issued and outstanding as of November 6, 2024, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 7, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    TRV V - 0 TRV GP V - 0 TRV GP V LLC - 0 TRV VI - 0 TRV GP VI - 0 TRV GP VI LLC - 0

     (ii) Shared power to vote or to direct the vote:

    TRV V - 7,135,233 shares TRV GP V - 7,135,233 shares TRV GP V LLC - 7,135,233 shares TRV VI - 969,218 shares TRV GP VI - 969,218 shares TRV GP VI LLC - 969,218 shares

     (iii) Sole power to dispose or to direct the disposition of:

    TRV V - 0 TRV GP V - 0 TRV GP V LLC - 0 TRV VI - 0 TRV GP VI - 0 TRV GP VI LLC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    TRV V - 7,135,233 shares TRV GP V - 7,135,233 shares TRV GP V LLC - 7,135,233 shares TRV VI - 969,218 shares TRV GP VI - 969,218 shares TRV GP VI LLC - 969,218 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Third Rock Ventures V, L.P.
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, COO of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P., general partner of Third Rock Ventures V, L.P.
    Date:02/13/2025
     
    Third Rock Ventures GP V, L.P.
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P
    Date:02/13/2025
     
    TRV GP V, LLC
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, Chief Operating Officer of TRV GP V, LLC
    Date:02/13/2025
     
    Third Rock Ventures VI, L.P.
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, COO of TRV GP VI, LLC, general partner of Third Rock Ventures GP VI, L.P., general partner of Third Rock Ventures VI, L.P.
    Date:02/13/2025
     
    Third Rock Ventures GP VI, L.P.
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, Chief Operating Officer of TRV GP VI, LLC, general partner of Third Rock Ventures GP VI, L.P.
    Date:02/13/2025
     
    TRV GP VI, LLC
     
    Signature:/s/ Kevin Gillis
    Name/Title:Kevin Gillis, Chief Operating Officer of TRV GP VI, LLC
    Date:02/13/2025
    Get the next $RAPP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    2/2/2026$43.00Overweight
    Wells Fargo
    11/19/2025$47.00Buy
    BTIG Research
    9/16/2025$44.00Buy
    Truist
    8/6/2025$31.00Buy
    H.C. Wainwright
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

    U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026  On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision

    1/7/26 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST. A live and archived webcast of the presentation will be available in the "Investors" section of the company's website at: https://investors.rapportrx.com. About Rapport Therapeutics Rapport Therapeutics is a clinical-stag

    12/18/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures

    Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease severity  RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced new data and post hoc

    12/5/25 9:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Rapport Therapeutics with a new price target

    Wells Fargo initiated coverage of Rapport Therapeutics with a rating of Overweight and set a new price target of $43.00

    2/2/26 6:52:08 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Rapport Therapeutics with a new price target

    BTIG Research initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $47.00

    11/19/25 8:58:22 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Rapport Therapeutics with a new price target

    Truist initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $44.00

    9/16/25 8:09:40 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Rapport Therapeutics Inc.

    SCHEDULE 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    1/21/26 12:30:31 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Rapport Therapeutics Inc.

    144 - Rapport Therapeutics, Inc. (0002012593) (Subject)

    1/15/26 4:28:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

    1/7/26 8:35:07 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    2/4/26 4:15:33 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Ceesay Abraham

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    2/4/26 4:14:58 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Ignelzi Troy A.

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    2/4/26 4:12:21 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Huber Reid M bought $499,374 worth of shares (20,400 units at $24.48) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:09 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paul Steven M bought $1,027,111 worth of shares (41,666 units at $24.65) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Young Wendy B. bought $79,100 worth of shares (3,500 units at $22.60), increasing direct ownership by 58% to 9,500 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/11/25 6:13:48 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Financials

    Live finance-specific insights

    View All

    Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

    Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today

    9/8/25 6:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

    BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other

    9/5/25 4:05:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 5:13:31 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

    SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 3:11:15 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/13/24 12:26:41 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

    3/11/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

    BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

    3/3/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care